← Mechanisms of action
S
SINGLE PROTEINSevere acute respiratory syndrome coronavirus 2
Preferred name: Spike glycoprotein ChEMBL ↗
Linked proteins
Drugs acting on this target (59)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| abo1020 | Antagonist | experimental | Vaccine | Spike glycoprotein antagonist |
| ABP-300 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| adg20 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| AZD3152 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| AZD5396 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| AZD8076 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| bamlanivimab | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| bi 767551 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| bms-986414 | Antagonist | experimental | Small molecule | Spike glycoprotein antagonist |
| c-135-ls | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| c144-ls | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| casirivimab | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| cor-101 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| covi-drops | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| ct-p63 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| ct-p66 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| fbr-002 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| giga-2050 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| igm-6268 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| imdevimab | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| imm-bcp-01 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| js026 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| ly-covmab | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| mad0004j08 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| regn14284 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| regn15160 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| sotrovimab (Xevudy) | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| sti-9199 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| tixagevimab (Evusheld) | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| tnx-2110 | Antagonist | experimental | Peptide | Spike glycoprotein antagonist |
| tnx-2120 | Antagonist | experimental | Peptide | Spike glycoprotein antagonist |
| tnx-2130 | Antagonist | experimental | Peptide | Spike glycoprotein antagonist |
| vir-7832 | Antagonist | experimental | mAb | Spike glycoprotein antagonist |
| cilgavimab (Evushield) | Blocker | experimental | mAb | Spike glycoprotein blocker |
| tixagevimab (Evusheld) | Blocker | experimental | mAb | Spike glycoprotein blocker |
| ad5-ncov | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| bivalent bnt162b2 (Comirnaty) | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| bivalent mrna-1273 (Spikevax bivalent) | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| bnt162b2 (Comirnaty) | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| covac-1 | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| covax-19 | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| covid19 recombinant spike protein | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| janssen SARS-CoV2 vaccine | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| mrna-1273 (Spikevax) | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| mvc-cov1901 | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| recombinant sars-cov-2 vaccine | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| sars-cov-2 adjuvanted recombinant protein vaccine (bivalent) | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| sars-cov-2 adjuvanted recombinant protein vaccine (monovalent) | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| sars-cov-2 fusion protein vaccine | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| sars-cov-2 mrna vaccine | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| sars-cov-2 protein subunit recombinant vaccine PT Biopharma | Immunity, active | experimental | Vaccine | Spike glycoprotein immunity, active |
| xav-19 | Immunity, passive | experimental | Animal product | Spike glycoprotein immunity, passive |
| casirivimab | Inhibitor | experimental | mAb | Spike glycoprotein inhibitor |
| Ensovibep | Inhibitor | experimental | Recombinant protein | Spike glycoprotein inhibitor |
| imdevimab | Inhibitor | experimental | mAb | Spike glycoprotein inhibitor |
| regdanvimab (Regkirona) | Inhibitor | experimental | mAb | Spike glycoprotein inhibitor |
| sotrovimab (Xevudy) | Inhibitor | experimental | mAb | Spike glycoprotein inhibitor |
| bnt162b2 (Comirnaty) | Vaccine antigen | experimental | Vaccine | Spike glycoprotein vaccine antigen |
| mrna-1273 (Spikevax) | Vaccine antigen | experimental | Vaccine | Spike glycoprotein vaccine antigen |